The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review.
Garside
R
R
Peninsula Technology Assessment Group, Exeter, UK.
Round
A
A
Dalziel
K
K
Stein
K
K
Royle
P
P
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use*; D001549:Benzamides; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000191:economics / Q000627:therapeutic use; D000068877:Imatinib Mesylate; D016898:Interferon-alpha / Q000191:economics / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000191:economics*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000191:economics* / Q000627:therapeutic use*; D011743:Pyrimidines / Q000191:economics* / Q000627:therapeutic use*; D016896:Treatment Outcome; D006113:United Kingdom
D000970:Antineoplastic Agents; D001549:Benzamides; D016898:Interferon-alpha; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D006918:Hydroxyurea